Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Sex disparities in myelodysplastic syndromes: genotype, phenotype, and outcomes
There is limited research on the influence of sex on genotype, phenotype, and health outcomes of patients diagnosed with myelodysplastic syndromes (MDS). Prognostic models 1-4 used in clinical practice help guide treatment selection and patient education. There are multiple models with differing variables, highlighting the limitations of accurately predicting disease progression and survival. Current models do not include sex as a variable to further inform prognosis and treatment selection. Sex, as a biological variable, is determined by the presence or absence of the Y chromosome, hormones, and gene expression. (Source: ...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 16, 2023 Category: Hematology Authors: Sara M Tinsley-Vance, Najla Al Ali, Somedeb Ball, Luis E Aguirre, Akriti G Jain, Mohammad Omar Hussaini, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey Lancet, Eric Padron, David A Sallman, Rami S Komrokji Tags: Original article Source Type: research

Total body irradiation versus chemotherapy conditioning in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplant: a systematic review and meta-analysis
This study compares the efficacy and safety of TBI-based regimens and CHT-based conditioning in pediatric, adolescent, and young adult patients with ALL (0-24 years old). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 13, 2023 Category: Hematology Authors: Mohammad Ebad Ur Rehman, Asmi Chattaraj, Anber Mahboob, Zarnab Ijaz, Diana Franco, Muhammad Farhan, Kuldeep Dharma, Hassan Mumtaz, Sajeel Saeed, Jawad Basit, Muhammad Muaaz Aslam, Ahmad Iftikhar, Fatima Faraz, Faiz Anwer Tags: Review Article Source Type: research

Disease Monitoring In Multiple Myeloma
The outcome for multiple myeloma (MM) patients has significantly improved in the last two decades, mainly due to the use of novel drugs with a singular mechanism of action, including immunotherapy. This has sparked a new debate about the possibility of curing a substantial proportion of MM patients which implicitly entails the need for most sensitive tools for evaluating treatment efficacy and disease monitoring (minimal residual disease –MRD) both at the BM level (next generation flow cytometry and sequencing) and outside of the BM (MRI/PET-CT, mass spectrometry) (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 13, 2023 Category: Hematology Authors: Jens Hillengass, Tom Martin, Noemi Puig, Bruno Paiva, Saad Usmani, Shaji Kumar, Jesus San-Miguel Tags: Commentary Source Type: research

SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes
MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat in lower risk MDS. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 12, 2023 Category: Hematology Authors: Virginia O. Volpe, Guillermo Garcia-Manero, Rami S. Komrokji Tags: Review Article Source Type: research

State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes
MDS is a clonal stem cell neoplasm with a spectrum from lower risk disease to short term life threatening higher risk disease. The disease risk is dictated by clinical and molecular features. Majority of MDS patients including lower risk disease unfortunately succumb from disease related complications namely cytopenia. While cytopenias may be mild early upon diagnosis and can be surveilled, ultimately treatment is required. Anemia is the hall mark of disease and most common indication to treat in lower risk MDS. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 12, 2023 Category: Hematology Authors: Virginia O. Volpe, Guillermo Garcia Manero, Rami S. Komrokji Tags: Review Article Source Type: research